InflaRx registers up to $65 million in ordinary shares for at-the-market sales

InflaRx N.V. filed a prospectus supplement on August 14, 2026 to register additional ordinary shares having an aggregate offering price of up to $65,000,000, to be offered and sold through Leerink Partners LLC under a sales agreement originally dated June 28, 2024.¹ Leerink Partners is entitled to a commission of up to 3.0% of gross proceeds from shares sold under the agreement.¹ Shares trade on Nasdaq under "IFRX" and closed at $2.01 on August 13, 2026.¹

The company said its lead program remains izicopan, an oral C5aR1 inhibitor, and that it is running Phase 2 planning for izicopan in ANCA-associated vasculitis, describing that planning as ongoing without interruption across several countries.¹ It also said it is pursuing early proof-of-concept work for izicopan in a wider set of complement-related kidney diseases through open-label studies expected to start yielding data next year, including in atypical hemolytic uremic syndrome, IgA nephropathy, and C3 glomerulopathy.¹ Following a CHMP recommendation to revoke the marketing authorization for Tavneos in the EU, InflaRx said it is evaluating a broader AAV development and registration strategy in Europe and plans to engage the EMA on both vilobelimab and izicopan.¹

On financing, InflaRx reported holding cash and cash equivalents of €146.6 million along with €11.8 million in marketable securities as of June 30, 2026, for combined available funds of €158.4 million.¹ The company said based on that cash position it expects to fund operating and capital expenditure needs into the end of 2029.¹ Net tangible book value stood at $165.6 million, or $1.12 per share, based on 147,368,221 shares outstanding as of June 30, 2026.¹